As of May 9, 2025, the Bristol Myers Squibb stock's P/E ratio is 17.33. This takes into account the latest EPS of $2.68 and stock price of $46.45.
The PE ratio of Bristol Myers Squibb has averaged 43.27 over the last ten years. The current price-to-earnings ratio of 17.33 is 60% less than the historical average. Analyzing the last ten years, BMY's PE ratio reached its highest point in the Jun 2018 quarter at 221.36, when the price was $55.34 and the EPS was $0.25. The lowest point was recorded in the Jun 2019 quarter, when it reached 11.93 with a price of $45.35 and an EPS of $3.8.
Maximum annual increase: 358.93% in 2017
Maximum annual decrease: -82.81% in 2018
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | N/A | N/A | $56.56 | -$4.41 |
2023 | 13.22 | -45.44% | $51.31 | $3.88 |
2022 | 24.23 | 22.44% | $71.95 | $2.97 |
2021 | 19.79 | N/A | $62.35 | $3.15 |
2020 | N/A | N/A | $62.03 | -$3.99 |
2019 | 31.78 | 84.02% | $64.19 | $2.02 |
2018 | 17.27 | -82.81% | $51.98 | $3.01 |
2017 | 100.46 | 358.93% | $61.28 | $0.61 |
2016 | 21.89 | -70.09% | $58.44 | $2.67 |
2015 | 73.18 | 49.99% | $68.79 | $0.94 |
2014 | 48.79 | 43.21% | $59.03 | $1.21 |
2013 | 34.07 | 22.33% | $53.15 | $1.56 |
2012 | 27.85 | 72.23% | $32.59 | $1.17 |
2011 | 16.17 | 9.93% | $35.24 | $2.18 |
2010 | 14.71 | 211.65% | $26.48 | $1.8 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Mar 2025 | 22.76 | N/A | $60.99 | $2.68 |
Dec 2024 | N/A | N/A | $56.56 | -$4.41 |
Sep 2024 | N/A | N/A | $51.74 | -$3.59 |
Jun 2024 | N/A | N/A | $41.53 | -$3.25 |
Mar 2024 | N/A | N/A | $54.23 | -$3.09 |
Dec 2023 | 13.22 | -9.58% | $51.31 | $3.88 |
Sep 2023 | 14.62 | -13.59% | $58.04 | $3.97 |
Jun 2023 | 16.92 | -15.53% | $63.95 | $3.78 |
Mar 2023 | 20.03 | -17.33% | $69.31 | $3.46 |
Dec 2022 | 24.23 | 5.3% | $71.95 | $2.97 |
Sep 2022 | 23.01 | -9.16% | $71.09 | $3.09 |
Jun 2022 | 25.33 | -1.48% | $77 | $3.04 |
Mar 2022 | 25.71 | 29.91% | $73.03 | $2.84 |
Dec 2021 | 19.79 | N/A | $62.35 | $3.15 |
Sep 2021 | N/A | N/A | $59.17 | -$2.37 |
The current PE ratio of BMY is under its 3, 5 and 10-year averages.
BMY's PE ratio is less than its peer stocks LLY and ABBV, but it is above JNJ's and ABT's. Bristol Myers Squibb's current PE ratio of 17.33 is less than the average of its peers, which is 29.66.
Stock name | PE ratio | Market cap |
---|---|---|
MRK Merck & Co Inc | 11.67 | $201.96B |
PFE Pfizer Inc | 16.61 | $131.28B |
NVS Novartis AG | 16.92 | $213.47B |
JNJ Johnson & Johnson | 17.01 | $370.87B |
ABT Abbott Laboratories | 17.1 | $229.64B |
BMY Bristol Myers Squibb Co | 17.98 | $98.05B |
AMGN Amgen Inc | 24.87 | $147.74B |
AZN Astrazeneca plc | 27.47 | $213.75B |
LLY ELI LILLY & Co | 61.23 | $716.08B |
ABBV AbbVie Inc | 80.54 | $335.74B |
As of May 9, 2025, BMY stock has a price to earnings ratio of 17.33.
The 3-year average PE ratio for BMY stock is 20.02.
The 5-year average PE ratio for BMY stock is 20.56.
Over the last ten years, the quarterly PE ratio reached its highest level at 221.36 in the Jun 2018 quarter.
BMY's price to earnings ratio is currently 60% below its 10-year historical average.
To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (May 9, 2025), Bristol Myers Squibb's share price is $46.45. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $2.68. Therefore, Bristol Myers Squibb's price to earnings ratio for today is 17.33. PE RATIO(17.33) = STOCK PRICE($46.45) / TTM EPS($2.68)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.